Today, Monday April 23, Acarix is publishing its Annual Report for 2017.
For further information please contact:
Christian Lindholm, Interim CEO
Phone: +46 705 118333
This information is information that Acarix AB (publ) is obliged to make public pursuant to the EU
Market Abuse Regulation 596/2014. The information was submitted for publication, through the
agency of the contact person set out above, at 08:00 CET on 23 April 2018.
Notes to editors:
Acarix was established in 2009, and since 2010 investors Sunstone Life Science Ventures (DK) and
SEED Capital (DK) have supported it towards market introduction. Acarix was listed on Nasdaq First
North Premier in 2016 and has attracted a highly-experienced management team.
The Acarix CADScor®System combines ultra-sensitive acoustic detection of turbulent arterial flow
and myocardial movement with advanced algorithms in a portable device to provide a patientspecific score to non-invasively assess the risk for Coronary Artery Disease (CAD) in less than 10 minutes. The system has been clinically validated.
Acarix was establish in 2009 and is listed on Nasdaq First North Growth Market. Acarix's CADScor@System uses an advanced sensor placed on the skin above the heart to listen to the sounds of cardiac contraction movement and turbulent flow. It has been designed to be an all-in-on system in the sense that the heart signal will be recorded, processed, and displayed as a patient specific score, the CAD-score, on the device screen.